Clinical trials: Endometrial Serous Adenocarcinoma
NSCLC, Low Grade Serous Ovarian Cancer
Phase I Trial of Defactinib and VS-6766.
This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid…
- Conditions
- NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
- Trial name
- FRAME (NCT03875820)
- Testing
- VS-6766, Defactinib
- Where
- 5 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Ovarian Neoplasms, Colorectal Neoplasms
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy.
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer
- Trial name
- NCT00132704
- Testing
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Uterine Serous Carcinoma, Uterine Carcinoma
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.
- Conditions
- Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer
- Trial name
- NCT06369155
- Testing
- Azenosertib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Joyce Liu, MD
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
This phase II trial studies how well sunitinib malate works in treating patients with endometrial cancer that has come back after a period of improvement (recurrent) or has spread to other places in the body (metastatic).
- Conditions
- Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00478426
- Testing
- Sunitinib Malate
- Where
- 29 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT01737619
- Testing
- Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B [Akt] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01935973
- Testing
- Laboratory Biomarker Analysis, Trametinib, Uprosertib
- Where
- 22 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to…
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05256225
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 414 sites in United States, Puerto Rico and 1 more
- Volunteers
- 360 people
- Sponsor
- National Cancer Institute (NCI)
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer…
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative
- Trial name
- NCT02208375
- Testing
- Capivasertib, Laboratory Biomarker Analysis, Olaparib
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Carcinoma
Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation
Uterine serous carcinoma (USC) is an uncommon, but aggressive variant of endometrial carcinoma that has poor response to standard therapy.
- Trial name
- NCT04030000
- Testing
- Paclitaxel/Carboplatin, Pelvic radiation therapy
- Where
- United States
- Sponsor
- Northwell Health
Cervical Adenocarcinoma, Cervical Adenosarcoma
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma
- Trial name
- NCT02020707
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 67 sites in United States, China and 2 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Uterine Cancer
Uterine Papillary Serous Cancer (UPSC) Trial
This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer.
- Trial name
- NCT00147680
- Testing
- Paclitaxel, Carboplatin
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer.
- Conditions
- Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer
- Trial name
- NCT02874430
- Testing
- Metformin Hydrochloride, Doxycycline
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Uterine Serous Carcinoma
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least…
- Trial name
- ADAGIO (NCT04590248)
- Testing
- Adavosertib
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Endometrial Cancer, Papillary Serous Endometrial Carcinoma
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer.
- Conditions
- Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04080284
- Testing
- Niraparib
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Northwell Health
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)